Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
Status:
Completed
Trial end date:
2014-11-24
Target enrollment:
Participant gender:
Summary
This 9-week study aimed to determine the efficacy, safety, and tolerability of nabiximols
(Sativex®) as an adjunctive treatment, compared with placebo in relieving uncontrolled
persistent chronic pain in participants with advanced cancer.
Eligible participants were not required to stop any of their current treatments or
medications.
Phase:
Phase 3
Details
Lead Sponsor:
GW Pharmaceuticals Ltd.
Collaborator:
Otsuka Pharmaceutical Development & Commercialization, Inc.